Assessing progression and efficacy of treatment for diabetic retinopathy following the proliferative pathway to blindness: Implication for diabetic retinopathy screening in Taiwan

Diabetic Medicine

Volumn 20, Issue 9, 2003, Pages 727-733

  Liu, W J ^a   Lee, L T ^b   Yen, M F ^c   Tung, T H ^c   Williams, R ^d   Duffy, S W ^e   Chen, Tony Hsiu Hsi ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Diabetic retinopathy; Markov model; Screening

Indexed keywords

BLINDNESS; CONFIDENCE INTERVAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; EYE FUNDUS; FOLLOW UP; HIGH RISK PATIENT; HUMAN; OUTPATIENT DEPARTMENT; PARAMETER; PROLIFERATIVE RETINOPATHY; RETINA MACULOPATHY; REVIEW; SCREENING; TAIWAN; ADULT; ARTICLE; COMPUTER SIMULATION; DISEASE COURSE; EVALUATION; FEMALE; LASER COAGULATION; MALE; METHODOLOGY; MIDDLE AGED; PATIENT COMPLIANCE; PROBABILITY; RETROSPECTIVE STUDY; STATISTICS; THEORETICAL MODEL; TREATMENT OUTCOME; VISION TEST;

ADULT; BLINDNESS; COMPUTER SIMULATION; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LASER COAGULATION; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TAIWAN; TREATMENT OUTCOME; VISION SCREENING;

EID: 0642366762     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.01019.x     Document Type: Review

References (21)

1. DRS Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Am J Ophthalmol 1976; 81: 383-396.
2. Blankenship GW. Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Ophthalmology 1991; 98: 125-128.
3. ETDRS Research Group. Early photocoagulation for diabetic retinopathy. Ophthalmology 1991; 98: 766-785.
4. Ferris FL III. How effective is treatment for diabetic retinopathy? JAMA 1993; 269: 1290-1291.
5. Rohan TE, Frost CD, Wald NJ. Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment. Br Med J 1989; 299: 1198-1201.
6. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patents with type 2 diabetes mellitus. JAMA 2000; 283: 889-896.
7. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996; 124: 164-169.
8. Dasbach EJ, Fryback DG, Newcomb PA, Klein R, Klein BE. Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care 1991; 29: 20-39.
9. Foulds WS, McCuish A, Barrie T, Green F, Scobie IN, Ghafour IM et al. Diabetic retinopathy in the west of Scotland: its detection and prevalence, and the cost-effectiveness of a proposed screening program. Health Bull (Edin) 1983; 41: 318-326.
10. Kohner EM. The evolution and natural history of diabetic retinopathy. Int Ophthalmol Clin 1978; 18: 1-16.
11. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
12. Kalbfleisch D, Lawless JF. The analysis of panel data under a Markov assumption. J Am Stat Assoc 1985; 80: 863-871.
13. Chen THH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics 2000; 56: 167-172.
14. SAS Institute Inc. SAS/STAT User's Guide, Version 6, 4th edn, Vol. 2. Gary, NC: SAS Institute Inc., 1989.
15. Lindesy JK. Parametric Statistical Inference. Chapter 3, Likelihood. Oxford: Clarendon Press, 1996.
16. Etzioni RD, Conor RJ, Prorok PC, Self SG. Design and analysis of cancer screening trials. Stat Method Medical Res 1995; 4: 3-17.
17. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112: 1217-1228.
18. Williams R. Diabetes mellitus. In Stevens A, Raftery J eds. Health Care Needs Assessment. Oxford: Oxford University Press, 1994; 31-57.
19. British Diabetic Association. Guidelines on the Management of Diabetes in Primary Care. London: British Diabetic Association, 1994.
20. Clinical Standards Advisory Group. Standard of Clinical Care for People with Diabetes. London: HMSO, 1994.
21. Klein R, Klein BEK, Moss SE, Davis MD, DeMetes DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989; 107: 244-249.